Lichen Planus – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026
- Published Date : September 4, 2026
- Updated On : November 2, 2026
- Pages : 53
Lichen Planus Emerging Therapy and TPP Insights
Thelansis’s “Lichen Planus Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.
Lichen Planus Overview
Lichen planus (LP) is a chronic inflammatory disorder in which T cells attack basal cells of the skin or mucosal surfaces. It may affect the skin, mouth, genital mucosa, nails or scalp. Cutaneous LP often causes itchy, flat-topped, violaceous papules; oral disease may produce white lacy patches, painful erosions or ulcers. Scalp involvement can cause permanent scarring hair loss. Diagnosis is usually clinical and may be confirmed by biopsy; persistent oral lesions need surveillance because erosive oral LP carries a small risk of squamous-cell carcinoma. Treatment depends on site and severity. Potent topical corticosteroids are first-line for many cutaneous and oral forms; calcineurin inhibitors or systemic corticosteroids, retinoids and other immunomodulators may be used for refractory disease. No therapy is FDA-approved specifically for LP. JAK inhibitors and dual ITK/JAK3 inhibition are under study; efficacy and long-term safety remain unproven. Recurrence after treatment is common.
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by surveys* with physician / key opinion leaders:
- Survey findings are corroborated and enriched by insights from interviews with leading KOLs
*Survey is customized based on client requirements
Deliverables format:
- PowerPoint presentation
- MS Excel
Key business questions answered:
- Detailed emerging competitive landscape
- Pipeline analysis
- Target patients for emerging therapies
- Key companies
- Key mechanism of actions
- Launch date estimates, etc.
- Clinical trial landscape analysis
- Target patient segments
- Trial endpoints
- Trial design
- Recruitment criteria, etc.
- Unmet Needs and Opportunities
- Performance of key current therapies
- Top areas of unmet needs
- Opportunity sizing for key unmet needs
- Target Product Profiles
- Attributes and levels
- Physician likelihood of prescribing
- Expected patient shares
- KOL insights on key emerging therapies
- Level of awareness
- Expected use / line of therapy
- Extent to fulfil key unmet needs
- KOL quotes
Lichen Planus Emerging Therapy and TPP Insights
Thelansis’s “Lichen Planus Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.
Lichen Planus Overview
Lichen planus (LP) is a chronic inflammatory disorder in which T cells attack basal cells of the skin or mucosal surfaces. It may affect the skin, mouth, genital mucosa, nails or scalp. Cutaneous LP often causes itchy, flat-topped, violaceous papules; oral disease may produce white lacy patches, painful erosions or ulcers. Scalp involvement can cause permanent scarring hair loss. Diagnosis is usually clinical and may be confirmed by biopsy; persistent oral lesions need surveillance because erosive oral LP carries a small risk of squamous-cell carcinoma. Treatment depends on site and severity. Potent topical corticosteroids are first-line for many cutaneous and oral forms; calcineurin inhibitors or systemic corticosteroids, retinoids and other immunomodulators may be used for refractory disease. No therapy is FDA-approved specifically for LP. JAK inhibitors and dual ITK/JAK3 inhibition are under study; efficacy and long-term safety remain unproven. Recurrence after treatment is common.
Geography coverage:
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by surveys* with physician / key opinion leaders:
- Survey findings are corroborated and enriched by insights from interviews with leading KOLs
*Survey is customized based on client requirements
Deliverables format:
- PowerPoint presentation
- MS Excel
Key business questions answered:
- Detailed emerging competitive landscape
- Pipeline analysis
- Target patients for emerging therapies
- Key companies
- Key mechanism of actions
- Launch date estimates, etc.
- Clinical trial landscape analysis
- Target patient segments
- Trial endpoints
- Trial design
- Recruitment criteria, etc.
- Unmet Needs and Opportunities
- Performance of key current therapies
- Top areas of unmet needs
- Opportunity sizing for key unmet needs
- Target Product Profiles
- Attributes and levels
- Physician likelihood of prescribing
- Expected patient shares
- KOL insights on key emerging therapies
- Level of awareness
- Expected use / line of therapy
- Extent to fulfil key unmet needs
- KOL quotes
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.
2. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies – profiles and KOL insights
- Emerging therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key emerging therapies – profiles and KOL insights
3. Product Attribute Analysis
- Key takeaways
- Scientific attributes
- Commercial attributes
- Product positioning
4. Primary Market Research
- Current treatment landscape
- Key therapies vs. focused patient segment
- Key attributes and benefits
- Futures treatment landscape
- Current challenges
- Unmet needs
- Emerging therapies
- Key therapies vs. focused patient segment
- Key attributes and benefits
- Futures treatment landscape
- Unmet needs and KOL expectations
5. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
6. Regulatory and Reimbursement Environments (by country and payer insights)
7. Appendix (e.g., bibliography, methodology)
Table of contents (TOC)
1. Key Findings and Analyst Commentary
- Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.
2. Competitive Landscape
- Current therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key current therapies – profiles and KOL insights
- Emerging therapies
- Key takeaways
- Dx and Tx journey/algorithm
- Key emerging therapies – profiles and KOL insights
3. Product Attribute Analysis
- Key takeaways
- Scientific attributes
- Commercial attributes
- Product positioning
4. Primary Market Research
- Current treatment landscape
- Key therapies vs. focused patient segment
- Key attributes and benefits
- Futures treatment landscape
- Current challenges
- Unmet needs
- Emerging therapies
- Key therapies vs. focused patient segment
- Key attributes and benefits
- Futures treatment landscape
- Unmet needs and KOL expectations
5. Unmet Need and TPP Analysis
- Top unmet needs and future attainment by emerging therapies
- TPP analysis and KOL expectations
6. Regulatory and Reimbursement Environments (by country and payer insights)
7. Appendix (e.g., bibliography, methodology)
